FDA May Seek More Authority To Require Post-Marketing Safety Studies
Executive Summary
FDA may consider asking for more authority to compel companies to undertake post-marketing drug safety studies after examining manufacturers' compliance with existing Phase IV commitments
You may also be interested in...
A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83
Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.
Post-Marketing Progress: Drug Industry Is Meeting Phase IV Commitments, FDA Says
FDA’s John Jenkins disputes accusations that the pharmaceutical industry does not take post-marketing studies seriously and that the agency is lax on enforcement. According to updated data from FDA, Phase IV studies are being completed in a timely manner, Jenkins argues – and when they aren’t, the agency is taking action.
Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel
Drug manufacturers need more clarity from FDA regarding post-marketing studies, industry representatives told the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System